Vanguard Capital Management
LIMN

Vanguard Capital Management’s Liminatus Pharma LIMN Stock Holding History

Vanguard Capital Management’s Portfolio LIMN Stock Details LIMN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.55K Hold
50,440
– – ﹤0.01% 4064
2026
Q1 		$8.68K Buy
+50,440
New +$26.9K ﹤0.01% 4021

Other funds holding LIMN

XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
SG
StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Personalized Indexing Management
Vanguard Personalized Indexing Management Oakland, California $12.2B AUM 47.93% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Vanguard Capital Management's LIMN Position: Q2 2026 in Review

Vanguard Capital Management held its Liminatus Pharma (LIMN) position steady in Q2 2026 at 50,440 shares worth $5.55K. The position accounts for ﹤0.01% of the portfolio, ranked #4064.

Vanguard Capital Management first reported a position in LIMN in Q1 2026 and has held it in 2 quarters since. The position peaked at $8.68K in Q1 2026. 13 funds tracked by Wall St. Rank hold LIMN as of Q2 2026.

  • Vanguard Capital Management held 50,440 shares of Liminatus Pharma worth $5.55K as of Q2 2026.
  • Vanguard Capital Management left its Liminatus Pharma share count unchanged in Q2 2026.
  • Liminatus Pharma made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #4064 holding.
  • Vanguard Capital Management first reported a position in Liminatus Pharma in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's Liminatus Pharma position peaked at $8.68K in Q1 2026.
  • 13 funds tracked by Wall St. Rank held Liminatus Pharma as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.